scholarly journals Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease

2018 ◽  
Vol 15 (1) ◽  
Author(s):  
Prahlad K. Rao ◽  
Kate Merath ◽  
Eugene Drigalenko ◽  
Avinash Y. L. Jadhav ◽  
Richard A. Komorowski ◽  
...  
Keyword(s):  
Liver Disease ◽  
High Density Lipoprotein ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Density Lipoprotein ◽  
High Density ◽  
Alcoholic Fatty Liver ◽  
Lipoprotein Particles ◽  
Alcoholic Fatty Liver Disease

scholarly journals Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yuta Yoshimura ◽  
Masahide Hamaguchi ◽  
Yoshitaka Hashimoto ◽  
Takuro Okamura ◽  
Naoko Nakanishi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
High Density Lipoprotein ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Density Lipoprotein ◽  
High Density ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background Hepatic steatosis has a pivotal role in the development of chronic liver diseases, even in alcohol-related liver disease. Alcoholic fatty liver disease is an important phenotype among alcohol-related liver diseases. While metabolic syndrome is a dominant risk factor of incident nonalcoholic fatty liver disease, the role of metabolic syndrome in alcoholic fatty liver disease has not been clarified yet. Methods A retrospective cohort study was performed at a health check-up center in Japan. Subjects consisted of male participants without fatty liver who consumed ethanol of 420 g/week or higher. Adjusted hazard ratios and 95% confidence intervals at the baseline examinations for incident alcoholic fatty liver disease were estimated using Cox model. Results A total of 640 participants were included in this study. During 3.91 years (IQR 1.63–7.09) of follow-up, 168 new cases of alcoholic fatty liver disease developed (49.1 cases per 1000 persons per year). After adjustment for age, smoking status, alcohol consumption, the hazard ratio for a 1 kg/m2 increase in body mass index was 1.2 (1.12–1.28). The hazard ratio of subjects with high triglyceride and low high-density lipoprotein-cholesterol levels were 1.56 (1.12–2.18) and 1.52 (1.03–2.25), respectively. Conclusions Obesity, high triglyceridemia, and low high-density lipoprotein-cholesterolemia are independent risk factors of alcoholic fatty liver disease in Japanese men who consumed alcohol habitually. In people with these risks, triglyceride lowering and high-density lipoprotein-cholesterol raising by improving insulin resistance and weight maintenance in addition to abstinence from alcohol would be effective in preventing the development of alcoholic fatty liver disease.

scholarly journals THE CORRELATION OF NECK CIRCUMFERENCE AND INSULIN RESISTANCE IN NAFLD PATIENTS

2019 ◽  
Vol 56 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Laura BOEMEKE ◽  
Fabiana Viegas RAIMUNDO ◽  
Márcia BOPP ◽  
Lara Rigon LEONHARDT ◽  
Sabrina Alves FERNANDES ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Density Lipoprotein ◽  
High Density ◽  
Abdominal Circumference ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

ABSTRACT BACKGROUND: Insulin resistance, especially that induced by obesity, plays a central role in the development of non-alcoholic fatty liver disease. Although the evaluation of overweight patients is important, the nutritional assessment tools used in clinical practice have limitations. Neck circumference (NC), from this, becomes a viable and low-cost alternative, which seems to be related to the accumulation of fat in the hepatic tissue. OBJECTIVE: To evaluate the association between NC and metabolic alterations in patients with non- alcoholic fatty liver disease. METHODS: A cross-sectional study performed in 82 patients, of whom 76 underwent liver biopsy. We performed weight, height, abdominal circumference and NC measures. Values of NC ≥42 cm and ≥36 cm were considered as altered for men and women, respectively. Laboratory tests and liver biopsy result were collected in the participants’ charts. We evaluated fasting blood glucose levels, insulin, glycosylated hemoglobin, triglycerides, total cholesterol, high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), ferritin, alkaline phosphatase, gamma glutamyltransferase, albumin, total bilirubin, direct bilirubin, glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase and the HOMA-IR index. RESULTS: We evaluated eighty-two patients. Patients with altered NC had increased body mass index (P=0.043), abdominal circumference (P=0.007), insulin (P=0.003) and HOMA-IR (P=0.029) when compared to those with adequate NC. NC was significantly correlated with reduced levels of high-density cholesterol (HDL-C) in men (r= -042, P<0.05), increased insulin levels in men and female (rs=0.47; P<0.05 and rs=0.51; P<0.01, respectively), as well as higher HOMA-IR index both males (rs=0.49; P<0.01) and female (rs=0.30; P<0.05). There was no significant association between NC and liver outcomes (r=0.145; P=0.36). CONCLUSION: NC is associated with the HOMA-IR index in patients with non-alcoholic fatty liver disease. NC can be used in the screening of insulin resistance in these patients, considering that insulin resistance plays a key role in the progression of the disease.

scholarly journals Lipid profile in different grades of Ultrasonic Non-Alcoholic Fatty Liver Disease

2017 ◽  
Vol 13 (2) ◽  
pp. 258-261 ◽  
Author(s):  
Khem Raj Bhusal ◽  
Rabindra Simkhada ◽  
Pramod Nepal
Keyword(s):  
Liver Disease ◽  
High Density Lipoprotein ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
P Value ◽  
Low Density ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background & Objectives: This study was conducted with objective of studying the lipid abnormalities in patients with non-alcoholic fatty liver disease diagnosed on the basis of ultrasound.Materials & Methods: Total 100 patients consisting of 67 males and 37 females diagnosed as Non-alcoholic fatty liver disease on the basis of ultrasound were included in the study. Laboratory values of different lipid parameters were compared in different grades of these patients.Results: Out of total 100 cases, mild nonalcoholic fatty liver disease was found in 83 %, moderate in 17 % and severe in none of the participants. Age of the participants ranged from 26 to 79 years with mean being 45 ± 11.99 years. Presence of dyslipidemia was found in 94 % of the cases. Triglycerides, total cholesterol and low density lipoprotein levels were raised in 59, 53, 72% of the cases respectively and High density lipoprotein level was decreased in 57% of participants. There was significant positive correlation of presence of non-alcoholic fatty liver disease with increasing levels of serum total cholesterol (P value <0.001), low density lipoprotein (P value <0.001) and triglyceride (P value <0.001) and significantly decreasing high density lipoprotein (P value <0.001). Whereas increasing grades of non-alcoholic fatty liver disease weren’t significantly associated with increasing level of lipid abnormalities.Conclusion: This study showed the high prevalence of dyslipidemia in non-alcoholic fatty liver patients. Early detection with simple non-invasive ultrasonography is very useful to detect dyslipidemic patients.

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

2017 ◽  
Vol 26 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Ahmed Elgebaly ◽  
Ibrahim A. I. Radwan ◽  
Mohamed M. AboElnas ◽  
Hamza H. Ibrahim ◽  
Moutaz F. M. Eltoomy ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomized Clinical Trials ◽  
Controlled Trial ◽  
Antioxidant Properties ◽  
Density Lipoprotein ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

Sign in / Sign up

Export Citation Format

Share Document